Genomics of Drug Sensitivity in Cancer |
Idelalisib
|
Synonyms |
CAL-101, Zydelig
|
Targets |
PI3Kdelta
|
Target pathway |
PI3K/MTOR signaling
|
PubCHEM ID |
11625818
|
Jsmol |
|
Download molecule |
11625818
|
PUBCHEM IUPAC INCHI |
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
|
Smiles |
FC5(=C4(C(=O)N(C1(=CC=CC=C1))C(C(NC2(=NC=NC3(=C2NC=N3)))CC)=NC4=CC=C5))
|
Cluster number |
67
|
calculated LogS |
-6,049
|
Molecular weight |
415,431
|
calculated LogP |
2,858
|
H-Acceptors |
8
|
H-Donors |
2
|
Ro5 violations |
0
|
Druglikeness |
1,6037
|
DrugScore |
8,18985670843582E-02
|
Mutagenic |
high
|
Tumorigenic |
high
|
Reproductive Effective |
low
|
Irritant |
high
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,3224
|
Rat Acute Toxicity |
2,7055
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,5227
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,62
|
AMES Toxicity |
AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,7103
|